Ken Griffin Addex Therapeutics Ltd. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.68 - $2.19 $4,760 - $15,330
-7,000 Reduced 16.91%
34,385 $32,000
Q4 2022

Feb 14, 2023
BUY
$0.55 - $18.0 $15,720 - $514,476
28,582 Added 223.24%
41,385 $26,000
Q3 2022

Nov 14, 2022
BUY
$0.78 - $16.4 $9,986 - $209,969
12,803 New
12,803 $10,000
Q1 2021

May 17, 2021
BUY
$9.82 - $14.11 $113,951 - $163,732
11,604 New
11,604 $121,000

About Addex Therapeutics Ltd.

ADXN Quotes by TradingView
  • Ticker ADXN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,204,630
  • Market Cap $65.6M
  • Description
  • Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs includ...
More about ADXN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email